Clinical experiences concerning the intramuscular contraceptive oxogestone.
D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006914:Hydroxysteroids / Q000008:administration & dosage / Q000009:adverse effects; D007273:Injections, Intramuscular; D007664:Ketosteroids / Q000008:administration & dosage / Q000009:adverse effects; D008796:Metrorrhagia / Q000139:chemically induced / Q000188:drug therapy; D009650:Norpregnanes / Q000008:administration & dosage*; D009652:Norpregnenes / Q000008:administration & dosage* / Q000009:adverse effects; D010666:Phenylpropionates / Q000008:administration & dosage / Q000009:adverse effects; D011247:Pregnancy; D011276:Pregnanediol / Q000652:urine; D014599:Uterus / Q000502:physiology
D003271:Contraceptive Agents, Female; D006914:Hydroxysteroids; D007664:Ketosteroids; D009650:Norpregnanes; D009652:Norpregnenes; D010666:Phenylpropionates; D004997:Ethinyl Estradiol; D011276:Pregnanediol